Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology
|
Buy Now
Retinal Degenerative Diseases - Mechanisms and Experimental Therapy (Hardcover, 1st ed. 2019)
Loot Price: R9,358
Discovery Miles 93 580
|
|
Retinal Degenerative Diseases - Mechanisms and Experimental Therapy (Hardcover, 1st ed. 2019)
Series: Advances in Experimental Medicine and Biology, 1185
Expected to ship within 12 - 17 working days
|
This book contains the proceedings of the XVIII International
Symposium on Retinal Degeneration (RD2018). A majority of those who
spoke and presented posters at the meeting contributed to this
volume. The blinding diseases of inherited retinal degenerations
have no treatments, and age-related macular degeneration has no
cures, despite the fact that it is an epidemic among the elderly,
with 1 in 3-4 affected by the age of 70. The RD Symposium focused
on the exciting new developments aimed at understanding these
diseases and providing therapies for them. Since most major
scientists in the field of retinal degenerations attend the
biennial RD Symposia, they are known by most as the "best" and
"most important" meetings in the field. The volume presents
representative state-of-the-art research in almost all areas of
retinal degenerations, ranging from cytopathologic, physiologic,
diagnostic and clinical aspects; animal models; mechanisms of cell
death; candidate genes, cloning, mapping and other aspects of
molecular genetics; and developing potential therapeutic measures
such as gene therapy and neuroprotective agents for potential
pharmaceutical therapy. While advances in these areas of retinal
degenerations were described, there will be many new topics that
either are in their infancy or did not exist at the time of the
last RD Symposium, RD2016. These include the role of inflammation
and immunity, as well as other basic mechanisms, in age-related
macular degeneration, several new aspects of gene therapy, and
revolutionary new imaging and functional testing that will have a
huge impact on the diagnosis and following the course of retinal
degenerations, as well as to provide new quantitative endpoints for
clinical trials. The retina is an approachable part of the central
nervous system (CNS), and there is a major interest in
neuroprotective and gene therapy for CNS diseases and
neurodegenerations, in general. It should be noted that with
successful and exciting initial clinical trials in neuroprotective
and gene therapy, including the restoration of sight in blind
children, the retinal degeneration therapies are leading the way
towards new therapeutic measures for neurodegenerations of the CNS.
Many of the successes recently reported in these areas of retinal
degeneration sprang from collaborations established at previous RD
Symposia, and many of those were reported at the RD2016 meeting and
included in the current volume. We anticipate the excitement of
those working in the field and those afflicted with retinal
degenerations is reflected in the volume.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.